{ "items": [ "\n\n
\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \nWe study the cellular and molecular events responsible for shepherding the development of protective antibodies during infection and after immunisation. Our main focus is the germinal centre reaction.
\n \n\n \n \n\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \nWe focus on the mechanisms controlling the migration of leucocytes and tumour cells via lymph in health and disease.
\n \n\n \n \n\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \nWe bring together biomedical, analytical and clinical expertise to shed new light on the causes that underpin neurodegenerative diseases.
\n \n\n \n \nWe are using a human genetic approach that relies on the latest developments of Next Generation Sequencing technology to study the intimate relationship that exists between the occurrence of new mutations and the regulation of cell fate choices in the male germline. Because life-long production of sperm is supported by regular divisions of so-called spermatogonial stem cells, each one of us acquire ~30-100 new mutations in our genome, the majority of which is paternal in origin.
\n \n\n \n \nThe ability to sequence whole exomes and genomes of individual people has revolutionised our ability to explore the full spectrum of genetic mutations causing serious human diseases. Working closely with the craniofacial teams based in Oxford and other UK units, we specialise in the application of these methods to children born with a serious malformation of the skull termed craniosynostosis.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nWe aim to discover the developmentally-regulated, molecular and biological properties of fetal haematopoietic stem and progenitor cells (HSPC) that provide the permissive cellular context for leukaemia and anemia in early childhood and to investigate the mechanisms which drive these changes.
\n \n\n \n \n\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \nWe are interested in how lymphocytes decide to mount immune responses against, for example, tumours. This involves trying to understanding how leukocyte receptors, such as the T-cell receptor and immune checkpoints, are triggered.
\n \n\n \n \n\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \nWe are investigating how iron and anaemia influence immunity and infectious diseases. Our research inspires treatments that control iron physiology to benefit the host at the expense of pathogens.
\n \n\n \n \n\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \nOur aims are to understand B cell development and diseases associated with abnormal antibody production. Inadequate or excessive immune responses lead to immunodeficiency or autoimmune and inflammatory diseases, which place a major economic and social burden on world health and the quality of human life. So, we are interested in the normal processes of immune function and how individuals vary due to inherited or acquired differences.
\n \n\n \n \nStudying DNA damage and repair to understand the causes of cancer and improve its treatment.
\n \n\n \n \nUsing genetic and epigenetic data to understand basic mechanisms of inflammation.
\n \n\n \n \nWe study the signalling mechanisms cells use to respond to DNA damage and why defects in these pathways cause human diseases such as cancer.
\n \n\n \n \n